NAP (Davunetide)
Overview
NAP, also known as davunetide, is an eight-amino acid peptide derived from activity-dependent neuroprotective protein (ADNP). It is thought to stabilize microtubules by interacting with tubulin and promoting cytoskeletal integrity, thereby protecting neurons from oxidative stress, excitotoxicity, and tauopathies. Intranasal delivery was pursued to achieve direct central nervous system access while minimizing systemic exposure.
Key Research Findings
Phase II trials in amnestic mild cognitive impairment and progressive supranuclear palsy were completed, but davunetide failed to meet primary cognitive or functional endpoints. A phase II/III trial in progressive supranuclear palsy was terminated early due to lack of efficacy, as reported in presentations at international conferences around 2012.
Intranasal
Investigational
Interested in NAP (Davunetide)?
Find a verified provider experienced with NAP (Davunetide) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a NAP (Davunetide) ProviderRelated Peptides
Semax
FDA ApprovedA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotective properties. Semax modulates BDNF and NGF expression, enhances monoaminergic neurotransmission, and provides neuroprotection through anti-oxidant and anti-inflammatory mechanisms. It crosses the blood-brain barrier via intranasal administration.
Selank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stability. Selank exhibits anxiolytic activity comparable to benzodiazepines without sedation, dependence, or withdrawal effects. It modulates the expression of BDNF, serotonin, dopamine, and norepinephrine, and influences IL-6 and GABA receptor expression.
Cerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis. It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration.
P21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neurogenesis and synaptic plasticity. P21 is a tetrapeptide that crosses the blood-brain barrier and enhances dentate gyrus neurogenesis by increasing BDNF expression. Unlike full-length CNTF, P21 does not activate the JAK-STAT pathway or produce the anorectic and immunogenic effects of the parent protein.